STOCK TITAN

[S-8 POS] Unity Biotechnology, Inc. SEC Filing

Filing Impact
(Low)
Filing Sentiment
(Neutral)
Form Type
S-8 POS
Rhea-AI Filing Summary

Unity Biotechnology filed Post-Effective Amendment No. 1 to terminate the effectiveness of multiple Form S-8 registration statements and remove from registration any shares of its common stock that remain unsold under those filings. The amendment lists each affected S-8 by file number and the original registered share amounts for various equity plans, and states the numbers do not reflect any interim corporate actions.

Unity Biotechnology ha presentato l'Emendamento Post-Effective n. 1 per cessare l'efficacia di più dichiarazioni di registrazione Form S-8 e rimuovere dalla registrazione le azioni ordinarie ancora non vendute relative a tali registrazioni. L'emendamento elenca ciascun S-8 interessato per numero di fascicolo e indica le quantità di azioni originariamente registrate per i diversi piani azionari, precisando che tali cifre non tengono conto di eventuali operazioni societarie intercorse.

Unity Biotechnology presentó la Enmienda Post-Effective n.º 1 para terminar la vigencia de varias declaraciones de registro Form S-8 y eliminar de registro las acciones ordinarias que queden sin vender bajo esos registros. La enmienda enumera cada S-8 afectado por número de expediente y las cantidades de acciones originalmente registradas para los distintos planes de capital, indicando que esos números no reflejan acciones corporativas intermedias.

Unity Biotechnology는 여러 건의 Form S-8 등록명세서의 효력을 종료하고 해당 서류에 따라 아직 판매되지 않은 보통주를 등록에서 제외하기 위해 Post-Effective Amendment No. 1을 제출했습니다. 해당 수정안은 영향받는 각 S-8을 파일 번호별로 나열하고 다양한 주식 보상 플랜에 대해 원래 등록된 주식 수를 기재하며, 이 수치들은 그 사이에 발생한 어떠한 회사 내 조치도 반영하지 않는다고 명시합니다.

Unity Biotechnology a déposé l'Amendement post-effective n°1 afin de mettre fin à l'effet de plusieurs déclarations d'enregistrement Form S-8 et de retirer de l'enregistrement les actions ordinaires encore invendues au titre de ces dépôts. L'amendement énumère chaque S-8 concerné par numéro de dossier et les montants d'actions initialement enregistrés pour les différents plans d'actions, en précisant que ces chiffres ne tiennent pas compte d'éventuelles opérations d'entreprise intervenues entre-temps.

Unity Biotechnology hat die Post-Effective Amendment Nr. 1 eingereicht, um die Wirksamkeit mehrerer Form S-8-Registrierungserklärungen zu beenden und nicht verkaufte Stammaktien aus diesen Eintragungen zu entfernen. Die Änderung führt jedes betroffene S-8 nach Aktenzeichen auf und nennt die ursprünglich für die verschiedenen Aktienprogramme registrierten Stückzahlen, wobei darauf hingewiesen wird, dass diese Zahlen keine zwischenzeitlichen Unternehmensmaßnahmen widerspiegeln.

Positive
  • None.
Negative
  • None.

Insights

TL;DR: The company formally deregistered unsold employee-plan shares across multiple S-8 filings; this is an administrative housekeeping action.

The filing terminates the effectiveness of several S-8 registration statements and removes unsold shares that had been reserved under various equity incentive and employee stock purchase plans. This action aligns the public registration record with the company's current capital plan and outstanding share availability. The amendment references specific prior S-8 file numbers and the originally registered share quantities but notes that listed amounts do not adjust for intervening corporate actions.

TL;DR: This is a routine securities deregistration; it carries no immediate financial metrics or transactional disclosures.

The document removes from registration the unsold portions of ten prior S-8 filings covering shares reserved for incentive awards and an employee purchase plan. No purchases, transfers, issuances or financial results are disclosed here; the filing serves to update the SEC record regarding what remains registered for public resale under those specific registration statements.

Unity Biotechnology ha presentato l'Emendamento Post-Effective n. 1 per cessare l'efficacia di più dichiarazioni di registrazione Form S-8 e rimuovere dalla registrazione le azioni ordinarie ancora non vendute relative a tali registrazioni. L'emendamento elenca ciascun S-8 interessato per numero di fascicolo e indica le quantità di azioni originariamente registrate per i diversi piani azionari, precisando che tali cifre non tengono conto di eventuali operazioni societarie intercorse.

Unity Biotechnology presentó la Enmienda Post-Effective n.º 1 para terminar la vigencia de varias declaraciones de registro Form S-8 y eliminar de registro las acciones ordinarias que queden sin vender bajo esos registros. La enmienda enumera cada S-8 afectado por número de expediente y las cantidades de acciones originalmente registradas para los distintos planes de capital, indicando que esos números no reflejan acciones corporativas intermedias.

Unity Biotechnology는 여러 건의 Form S-8 등록명세서의 효력을 종료하고 해당 서류에 따라 아직 판매되지 않은 보통주를 등록에서 제외하기 위해 Post-Effective Amendment No. 1을 제출했습니다. 해당 수정안은 영향받는 각 S-8을 파일 번호별로 나열하고 다양한 주식 보상 플랜에 대해 원래 등록된 주식 수를 기재하며, 이 수치들은 그 사이에 발생한 어떠한 회사 내 조치도 반영하지 않는다고 명시합니다.

Unity Biotechnology a déposé l'Amendement post-effective n°1 afin de mettre fin à l'effet de plusieurs déclarations d'enregistrement Form S-8 et de retirer de l'enregistrement les actions ordinaires encore invendues au titre de ces dépôts. L'amendement énumère chaque S-8 concerné par numéro de dossier et les montants d'actions initialement enregistrés pour les différents plans d'actions, en précisant que ces chiffres ne tiennent pas compte d'éventuelles opérations d'entreprise intervenues entre-temps.

Unity Biotechnology hat die Post-Effective Amendment Nr. 1 eingereicht, um die Wirksamkeit mehrerer Form S-8-Registrierungserklärungen zu beenden und nicht verkaufte Stammaktien aus diesen Eintragungen zu entfernen. Die Änderung führt jedes betroffene S-8 nach Aktenzeichen auf und nennt die ursprünglich für die verschiedenen Aktienprogramme registrierten Stückzahlen, wobei darauf hingewiesen wird, dass diese Zahlen keine zwischenzeitlichen Unternehmensmaßnahmen widerspiegeln.

As filed with the Securities and Exchange Commission on August 25, 2025

Registration No. 333-224726

Registration No. 333-230086

Registration No. 333-237088

Registration No. 333-237474

Registration No. 333-250926

Registration No. 333-254619

Registration No. 333-263576

Registration No. 333-270567

Registration No. 333-278679

Registration No. 333-285649

 

 
 

UNITED STATES

SECURITIES AND EXCHANGE COMMISSION

Washington, D.C. 20549

 

 

POST-EFFECTIVE AMENDMENT NO. 1 TO FORM S-8 REGISTRATION STATEMENT NO. 333-224726

POST-EFFECTIVE AMENDMENT NO. 1 TO FORM S-8 REGISTRATION STATEMENT NO. 333-230086

POST-EFFECTIVE AMENDMENT NO. 1 TO FORM S-8 REGISTRATION STATEMENT NO. 333-237088

POST-EFFECTIVE AMENDMENT NO. 1 TO FORM S-8 REGISTRATION STATEMENT NO. 333-237474

POST-EFFECTIVE AMENDMENT NO. 1 TO FORM S-8 REGISTRATION STATEMENT NO. 333-250926

POST-EFFECTIVE AMENDMENT NO. 1 TO FORM S-8 REGISTRATION STATEMENT NO. 333-254619

POST-EFFECTIVE AMENDMENT NO. 1 TO FORM S-8 REGISTRATION STATEMENT NO. 333-263576

POST-EFFECTIVE AMENDMENT NO. 1 TO FORM S-8 REGISTRATION STATEMENT NO. 333-270567

POST-EFFECTIVE AMENDMENT NO. 1 TO FORM S-8 REGISTRATION STATEMENT NO. 333-278679

POST-EFFECTIVE AMENDMENT NO. 1 TO FORM S-8 REGISTRATION STATEMENT NO. 333-285649

 

 

FORM S-8

REGISTRATION STATEMENT

Under

The Securities Act of 1933

 

 

UNITY BIOTECHNOLOGY, INC.

(Exact name of registrant as specified in its charter)

 

 

 

Delaware   26-4726035
(State or other jurisdiction of
incorporation or organization)
  (I.R.S. Employer
Identification Number)

124 Washington Street, Suite 101

Foxborough, Massachusetts 02035

(508) 543-1720

(Address of Principal Executive Offices)

Unity Biotechnology, Inc. 2013 Equity Incentive Plan

Unity Biotechnology, Inc. 2018 Incentive Award Plan

Unity Biotechnology, Inc. 2018 Employee Stock Purchase Plan

Unity Biotechnology, Inc. 2020 Employment Inducement Incentive Award Plan

(Full Title of the Plans)

Craig R. Jalbert

President, Secretary, and Director

Unity Biotechnology, Inc.

124 Washington Street, Suite 101

Foxborough, Massachusetts 02035

(508) 543-1720

(Name and address, including zip code, and telephone number, including area code, of agent for service)

 

 

Copies to:

Erica Kassman

Latham & Watkins LLP

140 Scott Drive

Menlo Park, CA 94025

Telephone: (650) 328-4600

 

 

Indicate by check mark whether the registrant is a large accelerated filer, an accelerated filer, a non-accelerated filer, a smaller reporting company or an emerging growth company. See the definitions of “large accelerated filer,” “accelerated filer,” “smaller reporting company,” and “emerging growth company” in Rule 12b-2 of the Exchange Act.

 

Large accelerated filer      Accelerated filer  
Non-accelerated filer      Smaller reporting company  
     Emerging growth company  

If an emerging growth company, indicate by check mark if the registrant has elected not to use the extended transition period for complying with any new or revised financial accounting standards provided pursuant to Section 7(a)(2)(B) of the Securities Act. ☐

 

 
 


EXPLANATORY NOTE

DEREGISTRATION OF SECURITIES

This Post-Effective Amendment No. 1 (“Post-Effective Amendment No. 1”) filed by Unity Biotechnology, Inc., a Delaware corporation (the “Company”), removes from registration all shares of the Company’s common stock, par value $0.001 per share (the “Common Stock”), registered under the following Registration Statements on Form S-8 (each a “Registration Statement” and, collectively, the “Registration Statements”) filed with the U.S. Securities and Exchange Commission (the “Commission”) that remain unsold thereunder:

 

   

Registration Statement on Form S-8 (No. 333-224726), filed with the Commission on May 7, 2018, pertaining to the registration of (i) 5,293,729 shares of the Company’s Common Stock under the Company’s 2013 Equity Incentive Plan and 2018 Incentive Award Plan, (ii) 3,330,530 shares of the Company’s Common Stock under the Company’s 2018 Incentive Award Plan, and (iii) 536,242 shares of the Company’s Common Stock under the Company’s 2018 Employee Stock Purchase Plan.

 

   

Registration Statement on Form S-8 (No. 333-230086), filed with the Commission on March 6, 2019, pertaining to the registration of (i) 2,125,510 shares of the Company’s Common Stock under the Company’s 2018 Incentive Award Plan, and (ii) 424,143 shares of the Company’s Common Stock under the Company’s 2018 Employee Stock Purchase Plan.

 

   

Registration Statement on Form S-8 (No. 333-237088), filed with the Commission on March 11, 2020, pertaining to the registration of (i) 2,361,841 shares of the Company’s Common Stock under the Company’s 2018 Incentive Award Plan, and (ii) 472,271 shares of the Company’s Common Stock under the Company’s 2018 Employee Stock Purchase Plan.

 

   

Registration Statement on Form S-8 (No. 333-237474), filed with the Commission on March 30, 2020, pertaining to the registration of 1,100,000 shares of the Company’s Common Stock under the Company’s 2020 Employment Inducement Incentive Award Plan.

 

   

Registration Statement on Form S-8 (No. 333-250926), filed with the Commission on November 24, 2020, pertaining to the registration of 1,500,000 shares of the Company’s Common Stock under the Company’s 2020 Employment Inducement Incentive Award Plan, as amended.

 

   

Registration Statement on Form S-8 (No. 333-254619), filed with the Commission on March 23, 2021, pertaining to the registration of (i) 2,675,309 shares of the Company’s Common Stock under the Company’s 2018 Incentive Award Plan, and (ii) 532,480 shares of the Company’s Common Stock under the Company’s 2018 Employee Stock Purchase Plan.

 

   

Registration Statement on Form S-8 (No. 333-263576), filed with the Commission on March 15, 2022, pertaining to the registration of (i) 3,182,965 shares of the Company’s Common Stock under the Company’s 2018 Incentive Award Plan, and (ii) 629,919 shares of the Company’s Common Stock under the Company’s 2018 Employee Stock Purchase Plan.

 

   

Registration Statement on Form S-8 (No. 333-270567), filed with the Commission on March 15, 2023, pertaining to the registration of (i) 710,765 shares of the Company’s Common Stock under the Company’s 2018 Incentive Award Plan, (ii) 142,153 shares of the Company’s Common Stock under the Company’s 2018 Employee Stock Purchase Plan, and (iii) 300,000 shares of the Company’s Common Stock under the Company’s 2020 Employment Inducement Incentive Award Plan, as amended.

 

   

Registration Statement on Form S-8 (No. 333-278679), filed with the Commission on April 15, 2024, pertaining to the registration of (i) 839,248 shares of the Company’s Common Stock under the Company’s 2018 Incentive Award Plan, and (ii) 167,849 shares of the Company’s Common Stock under the 2018 Employee Stock Purchase Plan.


   

Registration Statement on Form S-8 (No. 333-285649), filed with the Commission on March 7, 2025, pertaining to the registration of (i) 843,260 shares of the Company’s Common Stock under the Company’s 2018 Incentive Award Plan, and (ii) 168,652 shares of the Company’s Common Stock under the Company’s 2018 Employee Stock Purchase Plan.

As previously reported on June 27, 2025, the board of directors of the Company: (i) determined that it is in the best interests of the Company and its stakeholders that the Company be liquidated and dissolved in accordance with the Delaware General Corporation Law pursuant to a Plan of Complete Liquidation and Dissolution (the “Dissolution”); and (ii) approved seeking stockholder approval to proceed with the Dissolution pursuant to Delaware law at a special meeting of stockholders and, if approved by stockholders, file a Certificate of Dissolution with the Secretary of State of the State of Delaware. In connection with the foregoing, the Company has determined to terminate the offerings of securities under the Registration Statements. Accordingly, the Company is filing this Post-Effective Amendment No. 1 to terminate the effectiveness of the Registration Statements, and, in accordance with the undertakings made by the Company in the Registration Statements, to remove from registration any and all of the securities that remain unsold under the Registration Statements as of the date hereof. The Registration Statements are hereby amended, as appropriate, to reflect the deregistration of all such securities. Note that the numbers of securities listed above do not take into account any applicable corporate actions, such as stock splits, that may have been taken in the interim.


SIGNATURES

Pursuant to the requirements of the Securities Act of 1933, the registrant certifies that it has reasonable grounds to believe that it meets all of the requirements for filing on Form S-8 and has duly caused this Post-Effective Amendment No. 1 to the Registration Statements to be signed on its behalf by the undersigned, thereunto duly authorized, in the City of Foxborough in the Commonwealth of Massachusetts, on August 25, 2025.

 

UNITY BIOTECHNOLOGY, INC.
By:   /s/ Craig R. Jalbert
  Title: President, Secretary, and Director

No other person is required to sign this Post-Effective Amendment No. 1 to the Registration Statements on Form S-8 in reliance on Rule 478 of the Securities Act of 1933, as amended.

FAQ

What did Unity Biotechnology (UBX) file in this S-8 post-effective amendment?

The company filed Post-Effective Amendment No. 1 to terminate the effectiveness of multiple Form S-8 registration statements and to remove any unsold shares registered under those statements.

Which types of shares were removed from registration?

Shares of Unity Biotechnology common stock that were registered for issuance under various equity incentive plans and the employee stock purchase plan were removed from registration if unsold.

How many S-8 registration statements are affected?

The filing lists ten S-8 registration statements by file number that are being terminated and from which unsold shares are being removed.

Does the filing report any new issuances or financial impact?

No. The amendment only terminates the registration statements for unsold shares and does not disclose any issuances, sales, financial results, or other transactions.

Does the filing adjust the listed share amounts for stock splits or corporate actions?

No. The filing explicitly notes that the listed numbers do not take into account any applicable corporate actions, such as stock splits, that may have occurred in the interim.
Unity Btech

NASDAQ:UBX

UBX Rankings

UBX Latest News

UBX Latest SEC Filings

UBX Stock Data

5.13M
16.88M
1.9%
17.19%
3.33%
Biotechnology
Pharmaceutical Preparations
Link
United States
SOUTH SAN FRANCISCO